- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Alzheimer’s disease drug development landscape ; volume:13 ; number:1 ; day:11 ; month:11 ; year:2021 ; pages:1-9 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (11.11.2021), 1-9, 12.2021
- Urheber
-
Bokhoven, Pieter van
Wilde, Arno de
Vermunt, Lisa
Leferink, Prisca S.
Heetveld, Sasja
Cummings, Jeffrey
Scheltens, Philip
Vijverberg, Everard G. B.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-021-00927-z
- URN
-
urn:nbn:de:101:1-2022012306503264363317
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bokhoven, Pieter van
- Wilde, Arno de
- Vermunt, Lisa
- Leferink, Prisca S.
- Heetveld, Sasja
- Cummings, Jeffrey
- Scheltens, Philip
- Vijverberg, Everard G. B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
Geroscience and Alzheimer’s Disease Drug Development
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in Drug Therapy for Alzheimer’s Disease
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Alzheimer’s Disease
Non-drug Therapies for Alzheimer’s Disease: A Review
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
Geroscience and Alzheimer’s Disease Drug Development
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in Drug Therapy for Alzheimer’s Disease
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Alzheimer’s Disease
Non-drug Therapies for Alzheimer’s Disease: A Review
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
Geroscience and Alzheimer’s Disease Drug Development
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in Drug Therapy for Alzheimer’s Disease
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Alzheimer’s Disease